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Abstract The cellulases ceHobiohydrolase 1 (CBH 1) and 
endoglucanase 1 (EG 1) from the fungus Trichoderma reesei 
are closely related with 40% sequence identity and very similar in 
structure. In CBH 1 the active site is enclosed by long loops and 
some antiparallel ~strands forming a 40 A long tunnel, whereas 
in EG 1 part of those loops are missing so that the enzyme has a 
more common active site groove. Both enzymes were immobilized 
on silica and these materials were used as chiral stationary 
phases for chromatographic separation of the enantiomers of two 
chiral drugs, propranolol and alprenolol. The CBH 1 phase 
showed much better resolution than did the EG 1 phase, 
suggesting that the tunnel structure of the protein may play an 
important role in the chiral separation. The chiral compounds 
were found to be competitive inhibitors of both enzymes when 
p-nitrophenyl lactoside (pNPL) was used as substrate. (S)- 
enantiomers howed stronger inhibitory effects and also longer 
retention time on the stationary phases than the (R)-enantiomers. 
The consistency between kinetic data and retention on the 
stationary phases clearly shows that the enzymatically active 
sites of CBH 1 and EG 1 are involved in chiral recognition. 
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1. Introduction 
The filamentous fungus Trichoderma reesei secretes a very 
efficient cellulolytic system which contains two exoglucanases 
(cellobiohydrolase (CBH) 1 and 2), at least four endogluca- 
nases (EG 1, EG 2, EG 3 and EG 5) and one 13-D-glucosidase 
[1,2]. All of these enzymes can act synergistically to degrade 
crystalline cellulose efficiently. CBH 1 is probably the key 
enzyme in fungal cellulose degradation. It comprises about 
60% of the total cellulolytic proteins of T. reesei and is also 
abundant in other cellulolytic fungi. It has also been shown 
that deletion of the CBH 1 gene has a drastic effect on the 
cellulolysis of T. reesei [3]. Most fungal cellulases have a com- 
mon structural organization where the main part of the en- 
zyme, the catalytic ore, is connected through a heavily gly- 
cosylated linker region to a small cellulose-binding domain 
(CBD) [4]. This gives the whole molecule an elongated tadpole 
shape (180 A in the case of CBH 1) [5]. The three-dimensional 
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structure of the binding domain has been solved in only one 
case, but there are good reasons to believe that the others are 
all folded in the same way on the basis of sequence identity 
[2,5]. The crystal structure of the CBH 1 catalytic domain 
reveals a large domain (434 residues) with the dimensions 
60 × 50 × 40 A. About one-third of the domain is folded into 
a 'l~-sandwich' composed of two anti-parallel [3-sheets. The 
rest of the protein consists of loops that connect he 13-strands. 
Some extensive loops stabilised by disulphide bridges, to- 
gether with the concave '13-sandwich' form a 40 ~, long tunnel 
where the active site is located [6]. 
The catalytic domains of CBH 1 and EG 1 show significant 
amino acid homology with 45% identity [7] and accordingly 
have similar 3-D structures [6,8]. The EG 1 catalytic domain 
(371 residues) has the same dimensions as CBH 1 and also has 
the two large anti-parallel I~-sheets forming a '13-sandwich'. 
The sequence alignment of CBH 1 and EG 1 showed that 
four deletions in EG 1 mapped to the tunnel-forming loops 
in CBH 1. As a result, EG 1 has its active site in a deep but 
open groove rather than a tunnel (Fig. 1). 
CBH 1 has been found to be an excellent chiral selector and 
its properties were recently reviewed [9]. It can be coupled to a 
solid support (silica or continuous bed) [l(L12] to form a 
chiral stationary phase (CSP) or used in a carrier-free solution 
in capillary electrophoresis [13]. A rather broad spectrum of 
racemic solutes can be resolved, but CBH 1 functions best 
with amino alcohols such as the drugs used to block [3-adre- 
nergic receptors, so called [3-blockers. In an attempt o loca- 
lize the chiral site of CBH 1, we found that both the binding 
and catalytic domains contained enantioselective sites for pro- 
pranolol, a [3-blocker, but that the major enantioselectivity for
propranolol and other solutes could be ascribed to the cata- 
lytic domain [14]. 
In view of the fact that the 3-D structures of the catalytic 
domains of both CBH 1 and EG 1 have been solved, and 
since previous data indicated that the active site of CBH 1 
was involved in the chiral recognition, we have undertaken 
this study to further define the chiral site of the proteins. 
2. Materials and methods 
2.1. Chemicals 
Rac-, (R)-, (S)-propranolol chloride and para-nitrophenyl-~-D-lacto- 
side (pNPL) were from Sigma Chemical Company (St. Louis, MO). 
(R)- and (S)-alprenolol chloride were provided from Astra H~issle 
(G6teborg, Sweden). All other chemicals used were of analytical 
grade. The water used was Millipore purified. Spherical diol-silica 
with a particle diameter of 10 ~tm, pore size 300 A, area 60 m2/g 
and containing 5 ~tmol/m 2 of diol was obtained from Perstorp Bioly- 
tica (Lund, Sweden). 
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2.2. Experimental pparatus 
Microtiter plates (96-well) were from Bibby Sterrilin Ltd. (Stone, 
Staffs, UK). Twelve-channel 50-300 gl pipette, 12-channel 5-50 gl 
pipette, 12 × 8 tips pipette tip racks, 8-well reservoirs for multichannel 
pipetting and Lab systems Multiskan MCC/340 (version 2.33) were 
from Lab systems (Helsinki, Finland). 
A Beckman 114M Solvent Delivery Module high-performance li- 
quid chromatographic pump (Beckman Instruments, Inc., Altex 
Scientific Operations, CA) and a 1 gl cell LDC/Milton Roy Spectro- 
monitor D, variable wavelength detector (LDC/Milton Roy, Riviera 
Beach, FL) connected to a Model BD40 recorder (Kipp and Zonen, 
The Netherlands) were used. The injector was a Rheodyne (Australia) 
model with a volume of 20 gl. The columns were made of stainless 
steel (Skandinaviska GeneTec AB, Kungsbacka, Sweden). A water 
bath type 02 PT 923 (Hero, Barkerod, Denmark) was used to thermo- 
stat the column at 21°C. The pH meter was a model E 623 equipped 
with a combined pH glass electrode (Metro, Wheres, Switzerland). 
The spectrophotometer was a model Shimadzu UV-160A (Kyoto, 
Japan). 
2.3. Experiment 
2.3.1. Purification of the proteins. Concentrated culture filtrate 
from the fungus Trichoderma reesei strain QM 9414 was obtained 
from ALKO Ltd., Research Laboratories (Helsinki, Finland). CBH 
1 and EG 1 were purified from the concentrated culture filtrate as 
described in [1,15]. The purity of the proteins was examined by 10% 
SDS-PAGE and they were regarded as pure when only one band 
could be seen in the gel. 
2.3.2. Inhibition experiment. The rate of production ofp-nitrophe- 
nol (pNP) from pNPL was determined with CBH 1 and EG 1 as 
catalysts in the presence of the enantiomers of alprenolol and propra- 
nolol as inhibitors. Microtiter plates (96-well) were used and the con- 
centration ofpNP was measured at 414 nm (e= 16590 M 1 era-l) 
using a Multiscan MCC/340 microtiter plate reader. The conditions 
were the following for CBH 1: pNPL concentration 0.2-5 mM, en- 
zyme concentration 2 ~tM, 0.1 M sodium acetate buffer, pH 5.0, 
temperature 20°C, (R)- and (S)-forms of propranolol and alprenolol 
0-1.25 mM. In the case of EG 1, KM and kcat were determined at: 
pNPL concentration 0.36-9 mM, EG 1 concentration 0.2 IxM, other 
conditions as above. The inhibition experiments with EG 1 were per- 
formed at: pNPL concentration 0.5-3 raM, EG 1 concentration 0.2 
~tM, and inhibitor concentrations 0.31-1.25 mM. The incubation time 
was 15 rain in all cases and the reaction was stopped by adding to the 
reaction mixture an equal volume of 0.5 M Na~CO3. 
Inhibition studies were also done at pH 6.8. Here the experiments 
were carried out in test tubes, Conditions: pNPL 0.4-3 mM, CBH 1 
concentration 2 ~M, sodium phosphate buffer, pH 6.8 (I= 0.1), (R)- 
alprenolol (0.83 mM) and (S)-alprenolol (0.2 mM), incubation time 
1 h, otherwise as above. The pNP formed was measured at 410 nm in 
a spectrophotometer. 
2.4. Blanks (without enzymes) served as background controls 
2.4.1. Preparation of CBH 1 and EG 1 columns. CBH 1 and EG 1 
were immobilized on silica and the columns (100 ×2.1 mm ID) were 
prepared as in [15], 
2.4.2. Calculation of kinetic parameters (KM, ko~t and Ki). Kinetic 
parameters KM, kc~t and Ki (inhibition constant) were derived by non- 
linear regression analysis using the 'Ultrafit' program (Biosoft, UK). 
The program-predefined equations for Michaelis-Menten Kinetics and 
Competitive Inhibition were used as well as the functions for Robust 
Weighting and Simple Weighting. 
3. Results 
The activity of CBH 1 and EG 1 on a soluble substrate, 
p-nitro-phenyl-[3-o-lactoside (pNPL), was measured in the ab- 
sence and in the presence of the (R)- and (S)-enantiomers of
two 13-blockers, propranolol and alprenolol, respectively. Both 
enzymes were inhibited by the drugs and the inhibition was 
competitive according to the Eadie-Hofstee plots (Fig. 2). The 
kinetic parameters, KM and kcat, and Ki, derived from the 
experiments through non-linear regression are shown in 
Table 1. 
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The inhibition constant is a direct measure of the inhibitory 
effect. The lower the Ki value, the stronger is the inhibition, 
i.e., the stronger is the binding of the compounds. From Table 
1 we see the following. (1) The (S)-enantiomers of both com- 
pounds are in all cases stronger inhibitors than are the corre- 
sponding (R)-enantiomers. This is valid for both CBH 1 and 
EG 1. (2) The (S)- and (R)-forms of propranolol are stronger 
inhibitors than are the corresponding forms of alprenolol, 
except for the (R)-forms on EG 1, where alprenolol is the 
stronger inhibitor. (One should note the high standard errors 
in the experiments with EG 1, which are due to the high KM 
value for the enzyme (around 20 raM) compared to the sub- 
strate concentrations that could be used (0.4~9 mM) owning 
to the limited solubility of the substrate.) (3) The inhibition is 
stronger for CBH 1 than for EG 1. (4) The inhibition is pH 
dependent and stronger at pH 6.8 than at pH 5.0 (CBH 1 and 
alprenolol). 
CBH 1 and EG 1 chiral stationary phases were used for the 
separation of racemic alprenolol and propranolol. Table 2 
shows the chromatographic data. With CBH 1-CSP the re- 
sults are completely consistent with the inhibition experi- 
ments, i.e. the stronger the inhibitor, the longer it is retained 
on the column. The difference in Ki between the (R)- and (S)- 
enantiomers i reflected in a good separation of both rac-al- 
prenolol and rac-propranolol at both pH 5.0 and 7.0. Also 
retention and separation increase with the pH, but the differ- 
ences are larger than expected from the inhibition results. For 
example, the Ki value of (R)-alprenolol at pH 6.8 is only 
slightly higher than that of (S)-alprenolol at pH 5.0, but the 
(R)-form is retained much longer at pH 7.0 than is the (S)- 
form at pH 5.0. 
With EG 1-CSP we see similar trends as with CBH 1. Pro- 
pranolol is retained longer than alprenolol and the retention 
increases with pH. But on EG 1-CSP there is almost no sep- 
aration of the enantiomers as could be expected from the 
inhibition results. For example, the ratio between the Ki val- 
ues for the (R)- and (S)-forms of propranolol on EG 1 is 
almost the same as on CBH 1, whereas there is good separa- 
tion only on the CBH 1-CSP (Fig. 3). The retention of both 
forms of propranolol is fairly long also on the EG I-CSP. 
Table 1 
Comparison of inhibition 
pranolol and alprenolol 
experiments on CBH 1 and EG 1 by pro- 
Parameters CBH 1 EG 1 
pH 5.0 
KM (mM) 1.21 _+0.080 
kc~t (s 1) 0.127 +0.0034 
Kt (mM) 
(R)-propranolol 0.49 + 0.0093 
(S)-propranolol 0.10 + 0.012 
(R)-alprenolol 1.00 + 0.072 
(S)-alprenolol 0.26 + 0.032 
pH 6.8 
KM (mM) 0.48 +0.038 
kc~t (s -1) 0.0060 + 0.00013 
Ki (mM) 
(R)-alprenolol 0.31 + 0.040 
(S)-alprenolol 0.01 + 0.0050 
20.6 + 1.5 
8.20 + 0.046 
7.09+2.6 
1.49+0.15 
6.04 + 1.2 
3.77 + 0.77 
Experimental conditions are described in detail in Section 2.3.2. 
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Fig. 1. Structure of CBH 1. Schematic drawing of the CBH 1 Cot backbone. The view is roughly orthogonal to the inner [3-sheet of the 
sandwich. B-strands are shown as arrows and helices/loops as rattlers. Loop regions that are absent in the related EG 1 are indicated by darker 
colours. The three catalytic residures are drawn as ball-and-stick models. They all lie in the third B-strand from the right in the picture: Glu 217 
(top), Asp 214 (middle) and Glu 212 (bottom). The picture was created using the molecular graphics program O[18] and provided by Dr. Christina 
Divne (Uppsala University). 
4. Discussion 
Both CBH 1 and EG l are competitively inhibited by the 
[~-adrenergic blockers alprenolol and propranolol, indicating 
that these compounds must interact in close vicinity to the 
binding site of the substrate pNPL. With CBH 1 there is a 
clear correlation between the strength of the inhibition and 
the retention time on the column (Tables 1 and 2), which leads 
to our proposal that the main site for binding of these com- 
pounds and discrimination between the enantiomers overlaps 
with the active site. This is further supported by earlier find- 
ings showing that the separation of alprenolol was abolished 
in the presence of cellobiose or glucose in the mobile phase 
and that the presence of carboxymethyl cellulose impaired the 
resolution [12]. Cellobiose and glucose are also inhibitors of 
the activity of CBH 1 towards pNPL, glucose at high concen- 
trations whereas cellobiose is a strong inhibitor with a Ki 
value around 20 gM (data not shown). Similar phenomena 
were also found with CBH 2-CSP, where the capacity for 
chiral recognition was weakened in the presence of glucose 
and cellobiose in the mobile phase (unpublished results). 
On CBH 1 both (R)- and (S)-alprenolol had lower Ki val- 
ues, i.e. stronger binding, at pH 6.8 than at pH 5.0, indicating 
that electrostatic nteractions play an important role for bind- 
ing at the active site. Possible candidates for electrostatic n- 
teraction at the active site in the tunnel of CBH 1 are the three 
carboxylic residues that were proposed to be responsible for 
hydrolysis, Glu 212, Asp 214 and Glu 217 [6]. The glutamates 212 
and 217 are positioned on opposite sides of a hypothetical 
glycosidic bond, Glu m2 'below' and Glu 217 'above', with 
Asp zx4 on the side. Based on the negative potential that these 
residues should confer and their configurations, we suggest 
them to be the primary counterparts for electrostatic nterac- 
tion with the positively charged [~-blockers. Both alprenolol 
and propranolol are positively charged below their pKa (pH 
9.5) and the net charge is practically constant in the pH range 
used, so the observed increase in binding with pH is presum- 
ably caused by an increase in the negative potential at the 
Table 2 
Comparison of chromatography on CBH 1 and EG 1 phases 
Parameters CBH 1 EG 1 
(pH 5.0) (pH 7.0) (pH 5.0) (pH 7.0) 
k' 
0~ 
(R)-propranolol 2.52 50.17 5.48 24.6 
(S)-propranolol 8.18 292.4 5.96 28.8 
(R)-alprenolol 0.96 24.0 1.83 8.02 
(S)-alprenolol 5.72 233.8 1.91 8.91 
Propranolol 3.24 5.83 1,09 1.17 
Alprenolol 5.95 9.74 1.04 1.11 
Solid phases: CBH 1, silica; or EG 1, silica. 
Mobile phase: 0.01 M sodium acetate buffer, pH 5.0, or 0.01 M 
sodium phosphate buffer, pH 7.0. 
Flow rate: 0.2 mYmin. 
Column dimensions: 100 × 2.1 mm (ID). 
To obtain the retention times expressed as capacity factors, k', the 
(R)- and (S)-enantiomers were injected separately. The selectivity 
factors, ct, as a measure of the separation efficiency, is defined as 
= k's/k'R) [15]. 
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Fig. 2. Competitive inhibition of CBH 1 and EG 1 by R- and S-propranolol. (A,C) Reaction rate (v) versus concentration of the substrate 
p-nitro-phenyl lactoside ([pNPL]). (B,D) Eadie-Hofstee plot. The release ofp-nitrophenol by CBH 1 and EG 1 at 20°C in 0.1 M sodium acetate 
was measured as described in Section 2 in the presence of no inhibitor (11), R-propranolol (zx), or S-propranolol (O). The lines show the best 
fit obtained from the non-linear (A,C) or linear (B,D) regression analysis. 
active site. At least one of the carboxylic groups involved in 
the binding thus has a strongly perturbed pKa, probably 
Glu 217 the potential proton donor. The protonation states of 
the catalytic arboxylic groups in CBH 1 are not known, but 
they are so close that they are likely to affect each other so 
that the protonation of the whole system is spread over a 
broader pH range. Yet another esidue is likely to affect the 
charge at the active site, namely, His 22s, which is close to and 
probably forms a hydrogen bond to Asp 214. At low pH it 
would be positively charged and thus repel the positively 
charged amino group of the 13-blockers. Again the protona- 
tion state is not known. Free histidine has a pKa of 6.0, but 
here it is likely to be shifted upward because of the close 
contact with Asp 214. This would further broaden the pH range 
where the active site potential changes. Interestingly, it has 
been shown by micro-calorimetry that the enthalpy difference 
between binding of (S)- and (R)-alprenolol corresponds to 
the enthalpy for ionisation of one histidine residue [16]. 
Micro-calorimetric studies have also shown that the binding 
of alprenolol to CBH 1 increases with temperature [16] and so 
does the retention of propranolol on CBH 1-CSP [17]. The 
entropy term is thus the major factor in the binding energy 
which shows that hydrophobic interaction is also important. 
This is demonstrated here by the fact that propranolol, with 
its two-ring naphthyl group, is a stronger inhibitor than al- 
prenolol with a single aromatic ring. In the tunnel of CBH 1 
there are four tryptophans and the glycosyl unit binding sub- 
sites on each side of the catalytic arboxylates are both made 
up of tryptophan residues, Trp 36T and Tl'p 376. They are both 
at a suitable distance for interaction with the aromatic part of 
the 13-blockers. We suggest that the adrenergic 13-blockers bind 
primarily through their amino group to the catalytic arbox- 
ylates, and through the aromatic group to either of the tryp- 
tophans 367 or 376. Recent X-ray crystallographic data indi- 
cate that the naphthyl group of (S)-propranolol stacks to 
Trp 376 and that the amino group of the compound interacts 
with Glu 212 and Glu 217 in the active site of the enzyme (un- 
published result). 
There was no linear correlation between inhibition and re- 
tention with increasing pH. The Ki value of (R)-alprenolol is 
slightly higher at pH 6.8 (0.31) than that of (S)-alprenolol at 
pH 5.0 (0.26) (Table 1), but the (R)-form is retained almost 5 
times longer at pH 7.0 than is the (S)-form at pH 5.0 (Table 
2). This indicates that the retention must involve also other 
sites of interaction in addition to the specific binding at the 
active site and that the influence of these non-specific sites 
increases with pH. The binding could be inside the tunnel 
without interfering with the binding of the substrate, as well 
as on the outside of the protein. It is possible that the non- 
specific binding is caused by a general electrostatic interaction 
with the whole protein. In a previous work on the CBH 1- 
CSP by Marie et al [10] the pH dependence of the retention 
was investigated in detail, not only for [~-blockers but also for 
other charged compounds including acids and ampholytes and 
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Fig. 3. Chromatography of rac-propranolol and rac-alprenolol on CBH 1 and EG 1 columns. Solid phases: CBH 1-CSP and EG 1-CSP, re- 
spectively. Mobile phase: 0.01 M sodium acetate buffer, pH 5.0. Flow rate: 0.2 ml/min. Temperature: 21°C. Column dimensions: 100×2.1 mm 
ID. The asymmetric carbon is marked with an asterisk (*). 
a few uncharged compounds. All of the charged compounds 
were influenced by the pH over a broad range from pH 2.2 to 
8.1. CBH 1 has a low isoelectric point at around 3.9, above 
which it is negatively charged, and the surface net charge is 
rather high as judged from its behaviour in electrophoresis 
and ion-exchange chromatography. It is thus possible that 
the CBH 1-CSP to some extent acts as a weak cation exchan- 
ger. This unspecific mode of action is, however, not likely to 
provide a substantial chiral selectivity for the CSP. We pro- 
pose that specific binding inside the unique tunnel structure of 
CBH 1 is required for chiral recognition. 
Although the discussion above may explain the reason for 
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the binding of the B-blockers it does not provide the basis for 
the discrimination of the enantiomers. There are several pos- 
sibilities as to how this could be achieved. (1) Due to the 
strong binding the two enantiomers adopt the same confor- 
mation and thus the hydroxyl groups on the asymmetric car- 
bon would point in different directions and would interact 
differently with the protein. (2) Steric hindrance from the hy- 
droxyl group forces one of the enantiomers to adopt a con- 
formation that fits less well. (3) The enantiomers may bind in 
opposite directions in the tunnel. (4) The more retained (S)- 
enantiomer may adopt a conformation which mimics part of 
the hydrogen bonding configuration of a glycosyl ring, a con- 
formation that the (R)-enantiomer cannot adopt. To get a 
detailed understanding of the mechanism we probably need 
the crystallographic structure of a [3-blocker-CBH 1 complex 
combined with molecular dynamic simulation. 
The inhibition results (Table 1) show that the [3-blockers 
also bind at the active site of EG 1. The residues we suggested 
as most important for the interactions in CBH 1, the catalytic 
carboxylates, the histidine and the two tryptophan residues 
are also present in EG 1 [8] which therefore should fulfil the 
prerequisites for chiral discrimination discussed above for 
CBH 1. There is actually a difference in the Ki values of the 
enantiomers of both alprenolol and propranolol. The (S)-en- 
antiomers are in both cases stronger inhibitors showing that 
they have higher affinity for the active site than the corre- 
sponding (R)-form. Nevertheless, very low enantioselectivity 
was obtained on the EG 1-CSP. One explanation for this may 
be that a certain binding strength to the active site is required 
for the discrimination. The affinity of the compounds for the 
active site of EG 1 was only around one-tenth of that for 
CBH 1 (Table 1), and thus the specific interaction may be 
too weak to give a substantial impact on the total binding. 
In spite of the weaker inhibition of EG 1, the retention at 
pH 5.0 is not so very different on the two CSPs. The retention 
of the (R)-enantiomers were even shorter on the CBH 1-CSP 
(Table 2). The retention on the EG 1-CSP must therefore be 
governed to a larger extent by non-specific interactions out- 
side of the active site. A general electrostatic attraction could 
be involved, as discussed for CBH 1. EG 1 is also an acidic 
protein (pI 4.5) with a rather high net charge. 
The main difference between the proteins is that EG 1 lacks 
part of the extended loops that enclose the active site of CBH 
1. In EG 1 the active site lies in a deep groove rather than in a 
tunnel. The presence of the outer wall in CBH 1 is the most 
probable explanation for why it is much more efficient in 
separating the enantiomers. Electrostatic interactions between 
the compounds and the acidic residues is the main binding 
force, as mentioned above, but hydrogen-bonding and hydro- 
phobic interactions are probably involved as well [10]. More 
potential contact points will be provided by the extra amino 
acids in the tunnel oops of CBH 1, at the same time as they 
will restrict the access to the active site so that a better fit is 
required for binding. Furthermore, the binding within a tun- 
nel would exclude more water molecules from contact with 
the compounds and thus increase the entropic part of the 
binding. In a groove, part of the molecules would still be 
exposed to the solvent. The water molecules may form a local 
hydrophilic environment which could weaken the hydropho- 
bic interactions between the compounds and the residues in 
the active sites. 
5. Conclusion 
The [3-adrenergic blocking agents act as competitive inhibi- 
tors of CBH 1 and EG 1, indicating that the active sites are 
involved in the chiral recognition. The different chiral selec- 
tivity of CBH 1 and EG 1 shows that the tunnel structure of 
the protein is of vital importance for the chiral recognition. 
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